Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HALO
FechaHoraFuenteTítuloSímboloCompañía
08/05/202407:30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202415:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202415:01PR Newswire (US)HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/04/202415:45PR Newswire (US)Mahesh Krishnan Elected to Halozyme's Board of DirectorsNASDAQ:HALOHalozyme Therapeutics Incorporated
23/04/202407:30PR Newswire (US)Halozyme to Report First Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
04/03/202415:13Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HALOHalozyme Therapeutics Incorporated
28/02/202417:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
28/02/202415:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202415:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202415:01PR Newswire (US)HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
12/02/202405:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
08/02/202415:30PR Newswire (US)Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/01/202415:15PR Newswire (US)Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
18/01/202407:30PR Newswire (US)Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia GravisNASDAQ:HALOHalozyme Therapeutics Incorporated
16/01/202407:15PR Newswire (US)Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
16/01/202400:15PR Newswire (US)Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer TypesNASDAQ:HALOHalozyme Therapeutics Incorporated
12/01/202408:25PR Newswire (US)Halozyme to Host Investor Business Forum and Long-Term Outlook CallNASDAQ:HALOHalozyme Therapeutics Incorporated
27/11/202307:00PR Newswire (US)Halozyme to Present at Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/11/202308:00PR Newswire (US)Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia GravisNASDAQ:HALOHalozyme Therapeutics Incorporated
06/11/202315:01PR Newswire (US)HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
06/11/202306:30PR Newswire (US)Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's DiseaseNASDAQ:HALOHalozyme Therapeutics Incorporated
30/10/202317:35PR Newswire (US)Halozyme To Report Third Quarter 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
19/10/202306:15PR Newswire (US)Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell CarcinomaNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202314:05PR Newswire (US)Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery ConferenceNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202307:00PR Newswire (US)Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug DeliveryNASDAQ:HALOHalozyme Therapeutics Incorporated
29/08/202303:50PR Newswire (US)Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great BritainNASDAQ:HALOHalozyme Therapeutics Incorporated
08/08/202315:01PR Newswire (US)HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/07/202307:30PR Newswire (US)Halozyme To Report Second Quarter 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
17/07/202300:15PR Newswire (US)Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Su Consulta Reciente

Delayed Upgrade Clock